AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04280900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality-Enhanced Cognitive Behavioral Therapy (VR-CBT)
Description: use of cybertherapy (8 sessions) in addition to cognitive behavioral therapy (4 sessions) (pharmacological treatment are note modified)
Study NCT04280900 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Description: Treatment as usual is a cognitive behavioral therapy I (4 sessions) (pharmacological treatment are note modified)
Study NCT04280900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual is a cognitive behavioral therapy I (4 sessions) (pharmacological treatment are note modified)
Study NCT01999803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sNN0029
Study NCT01999803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00800332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT003-QbG10
Description: subcutaneous injection
Study NCT00800332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection
Study NCT02858414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional blood sample
Study NCT01040559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Transarterial chemoembolization (in the hepatic artery) with idarubicin 5mg or 10 mg or 15 mg or 20 mg or 25 mg injected in a solution of 2ml DC Bead (300 µm-500µm); 1 unique course
Study NCT02365714 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: CK Stereotactic Accelerated Partial Breast Irradiation
Description: Adjuvant radiation therapy will be delivered to the region of the lumpectomy cavity once daily for 5 treatments over 5-10 days.
Study NCT02976870 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Single ultrasound scan of kidney on side of body where ALIF was performed. If hydronephrosis of this kidney is detected, the second kidney will also be scanned.
Study NCT00916253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Modafinil is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):~* during 3 days at home~* during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day and 2 driving sessions (one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under treatment (Modafinil).
Study NCT00916253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):~* during 3 days at home~* during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day, and 2 driving sessions ( one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under Placebo.
Study NCT00094055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG013736
Description: AG013736, tablets 5 mg BID daily until tumor progression or toxicity
Study NCT04008407 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Submucosal Dissection
Description: Endoscopic Submucosal Dissection (ESD) results in en-bloc resection of LSL, regardless of lesion size. This allows for accurate histopathological assessment of SMIC, R0/R1 resection and depth of invasion. ESD is considered a potentially curative for superficial cancers (T1a).
Study NCT04008407 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Mucosal Resection
Description: EMR is the current standard for treating colonic LSL and has been validated to be safe and efficacious. LSLs => 20mm are frequently resected piecemeal. Recent research show that resection margin soft coagulation reduces recurrence rates to those similar to en-bloc resections.
Study NCT00599482 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Far Infrared Radiation (5μm to 20μm wavelength)
Description: Far infrared radiation for 30 to 40 minutes during each session.
Study NCT06476067 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Esophagectomy
Study NCT02286700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desonide Cream
Description: Study cream randomized and distributed to subjects, applied twice daily for 3 weeks and evaluated ability to reduce atopic dermatitis symptoms.
Study NCT02286700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amino Acid Moisturizing Cream
Description: Study cream randomized and distributed to subjects, applied twice daily for 3 weeks and evaluated ability to reduce atopic dermatitis symptoms.
Study NCT03490643 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Postural Analysis
Description: posture and plantar pressure analysis
Study NCT03490643 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: plantar pressure analysis
Description: posture and plantar pressure analysis
Study NCT01783119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aloe Barbadensis Miller
Study NCT01783119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo water
Study NCT03452371 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Navigators will also screen participants for barriers to smoking cessation. Patient navigation intervention calls will use motivational interviewing (MI) strategies to: (1) Assess stage of change; (2) Assess and reinforce any prior abstinence from smoking and/or any efforts made to reduce/quit smoking; (3) Explore motivation to quit smoking, drawing on recent illness, financial/family situations as appropriate; advise about the risks of smoking and benefits of quitting (4) Discuss past experience with utilizing cessation support; (5) Explore potential barriers to using smoking cessation medications; (6) Brainstorm strategies to address identified barriers; (7) Elicit commitment to accept another patient navigation counseling call, discuss timing.
Study NCT03452371 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Traditional Care
Description: Enhanced traditional care will include a resource card with information on quitlines, Boston Medical Center's (BMC's) Tobacco Treatment Center Program number, and websites for smoking cessation.
Study NCT01003496 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Outpatient substance abuse treatment
Study NCT01003496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU + Long-Term Recovery Management
Description: Long-Term Recovery Management (LTRM) combines 3 established treatment techniques (Community Reinforcement Approach, Contingency Management, and Facilitated Therapeutic Alliance), each with demonstrated efficacy, into a chronic disease model. In addition, patient cases are kept open, thereby removing potential obstacles to re-engagement with stepped-up care, when indicated. Patients randomly assigned to LTRM will be asked to participate in group sessions each month for 12 months.
Study NCT02791490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Oral tablet, 100 mg, once daily at approximately the same time each day
Study NCT02474342 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Adipose Tissue Derived MSCs Transplantation
Description: 1. Study drugs: Autologous adipose tissue derived MSCs~2. Injection dosage and volume of the study drugs:~   * Low dose: 1x10e7 cells/3mL~3. Number of injections : only once during the study period~4. Device: Ultrasound~5. Injection technique: Injection into the lesion by investigator
Study NCT02474342 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Adipose Tissue Derived MSCs Transplantation
Description: 1. Study drugs: Autologous adipose tissue derived MSCs~2. Injection dosage and volume of the study drugs:~   * Mid dose: 5x10e7 cells/3mL~3. Number of injections : only once during the study period~4. Device: Ultrasound~5. Injection technique: Injection into the lesion by investigator
Study NCT02474342 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Adipose Tissue Derived MSCs Transplantation
Description: 1. Study drugs: Autologous adipose tissue derived MSCs~2. Injection dosage and volume of the study drugs:~   * High dose: 1x10e8 cells/3mL~3. Number of injections : only once during the study period~4. Device: Ultrasound~5. Injection technique: Injection into the lesion by investigator
Study NCT02821702 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal ultrasound
Study NCT02821702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal ultrasound
Study NCT02821702 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Study NCT02821702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Study NCT02905474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual standard CKD care involves an outpatient clinic visit every 3 to 4 months (at minimum every 6 months) for a clinical assessment by their renal clinical care team.
Study NCT02905474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual standard CKD care involves an outpatient clinic visit every 3 to 4 months (at minimum every 6 months) for a clinical assessment by their renal clinical care team.
Study NCT02905474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated mobile medication app
Description: Use of mobile app to maintain, manage medication list on a smartphone device that allows for bidirectional transfer of medication information
Study NCT02905474 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available mobile medication app
Description: Use of mobile app to manually record and maintain medication records with no integration to databases.
Study NCT01246440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catumaxomab
Description: Catumaxomab: 4 intraperitoneal infusions of catumaxomab over 11 days administered in a period of 3 hours through an intraperitoneal catheter with the following dosage: 1) 10 µg on Day 0. 2) 20 µg on Day 3. 3) 50 µg on Day 7. 4) 200 µg on Day 10.
Study NCT03389854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RestoreX PTT - randomized and open label
Description: Penile traction therapy in the straight and bent positions
Study NCT03389854 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RestoreX PTT - open label phase only
Description: Penile traction therapy in the straight and bent positions
Study NCT00109707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Study NCT04509921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: asthma treatment adjustment taking account on degree of bronchial hyperresponsiveness
Description: Modification of inhaled corticosteroid dose based on the symptoms and the result of bronchial provocation (BHR group)
Study NCT03030430 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAT1706 injection
Description: 1mg/kg, IV on day 1
Study NCT03030430 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-sourced Avastin
Description: 1mg/kg, IV on day 1
Study NCT03030430 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-sourced Avastin
Description: 1mg/kg, IV on day 1
Study NCT01527214 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT scan and education
Description: GPs get direct access to chest CT scans for their patients. The GPs will be offered special training related to the diagnosis of lung cancer in general practice.This will be done by offering training sessions and written material. The training will include risk groups, alarm symptoms, symptom complexes and interpretation of CT scan descriptions.
Study NCT04027933 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Based on Standard Patient Simulation
Description: In the first phase of the study, a theoretical education was provided to the students.~In the second phase, the students in the experimental and control groups who completed their theoretical education were given data collection forms. In the third phase, after the scales were implemented, there was no intervention with the control group. There was a standard patient implementation to the experimental group. In the fourth phase of the study, after completing the simulation practice, all scales were re-applied both to the experimental and control groups. The scales were applied after the simulation training was completed and students were sent to the clinical practice after three weeks. In the fourth phase of the study, right before the students practiced their trainings and at the end of the initial rotations of the clinical practice, which turned out to be about four weeks later on average, all scales were re-applied both to the experimental and control groups.
Study NCT03728309 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM VOLITE™ XC
Description: Intradermal, needle in multiple microdepot injections across both cheeks.
Study NCT04243863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-7145
Description: Part 1: one dose Part 2: 28 doses (once every 8 hour \[q8h\] dosing for 9 days with a single morning dose on Day 10)
Study NCT04243863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1: one dose Part 2: 28 doses (once every 8 hour \[q8h\] dosing for 9 days with a single morning dose on Day 10)
Study NCT00736346 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief cognitive-behavioral treatment for Panic Disorder
Description: One two-hour session of cognitive-behavior therapy for panic disorder
Study NCT00736346 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavior Therapy for Panic Disorder
Description: Seven one-hour sessions of cognitive-behavior therapy for panic disorder
Study NCT00736346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine
Description: 40 mg die, for 6 months
Study NCT02555943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir
Description: Oral direct anti-HCV agent. Ledipasvir/Sofosbuvir(LDV/SOF) 400mg/90mg fixed-dose combination(FDC) tablet, administered orally once daily.
Study NCT02555943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ledipasvir/Sofosbuvir
Description: Oral direct anti-HCV agent. Ledipasvir/Sofosbuvir(LDV/SOF) 400mg/90mg fixed-dose combination(FDC) tablet, administered orally once daily.
Study NCT02555943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Daclatasvir
Description: TWO oral direct anti-HCV agent: Sofosbuvir(SOF), 400mg tablet administered orally once daily. Daclatavir(DCV), 60mg tablet administered orally once daily.
Study NCT02555943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir and Daclatasvir
Description: TWO oral direct anti-HCV agent: Sofosbuvir(SOF), 400mg tablet administered orally once daily. Daclatavir(DCV), 60mg tablet administered orally once daily.
Study NCT02555943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir
Description: VIEKIRA PAK includes ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, ritonavir, a CYP3A inhibitor and dasabuvir, a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor.
Study NCT02555943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir
Description: VIEKIRA PAK includes ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, ritonavir, a CYP3A inhibitor and dasabuvir, a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor.
Study NCT02555943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Nucleoside-inhibitor-treatment-naïve with compensated liver disease (greater than or equal to 16 years old): 0.5 mg once daily.
Study NCT02555943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Nucleoside-inhibitor-treatment-naïve with compensated liver disease (greater than or equal to 16 years old): 0.5 mg once daily.
Study NCT02555943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil
Description: VIREAD is indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older.
Study NCT02555943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil
Description: VIREAD is indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older.
Study NCT00408694 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT
Study NCT00408694 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00408694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT00408694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT00408694 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT03393767 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ranibizumab
Description: Intravitreal injection
Study NCT03220906 — intervention group
Intervention type: OTHER
Intervention: Blood pressure measurement
Description: Blood pressure will be measured in both upper and lower extremities.
Study NCT01417494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen)
Study NCT01417494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab
Study NCT02361632 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coffee with or without milk
Description: Intervention :30 participants were randomized to 3 Groups, 10 persons in each group. All participants fasted 6 hours for solid food before gastric volume was measured by Magnetic Resonance Imagining ( MRI). 2 hours before MRI examination, each participant ingested either 175 ml black coffee, 175 ml coffee with 20% milk or 175 ml coffee with 50% milk in the order defined for the group (arm).
Study NCT01305577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic acid injection
Study NCT01305577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline placebo for injection
Study NCT03059680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High potassium diet
Description: An increase in consumption of high potassium fruits and vegetables
Study NCT04252976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ethical Living
Description: Ethical principles based on Yoga philosophy, including contents of Yamas and Niyamas.
Study NCT04252976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Exercises
Description: Ujjaii breathing and simple yoga asanas
Study NCT04252976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mantra Meditation
Description: Meditation with mantras
Study NCT02745015 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: non-surgical periodontal treatment
Description: full-mouth scaling and root planing
Study NCT02745015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-surgical periodontal treatment
Description: full-mouth scaling and root planing
Study NCT00796978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
Study NCT00796978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Blood is collected every 6 weeks during treatment. Samples are assessed for plasma cardiac markers (N-terminal brain natriuretic protein and troponin-I) and pro-inflammatory cytokines (interleukin-6 and tumor necrosis factor-α).
Study NCT00796978 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
Study NCT00796978 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Patients complete Quality of Life and Quality of Health and Comprehensive Geriatric assessments of functional, cognitive, and mental status changes at baseline, weeks 26, and 52.
Study NCT02672293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phoslax
Description: Oral sodium phosphate solution (monobasic sodium phosphate 2.4 g and dibasic sodium phosphate 0.9g / 5 mL).
Study NCT03795272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: 2:1 randomization to receive rucaparib/placebo twice daily for 24 month